TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Industry Press release
Medicine Press release
Olympus Unveils Corporate Strategy
Nov 07, 2025 14:30 JST
Olympus Corporation (Olympus), a global MedTech leader dedicated to making people's lives healthier, safer, and more fulfilling, today unveiled a comprehensive strategy to transform endoscopy-enabled care through innovation and operational excellence.
More info..
Olympus Unveils Corporate Strategy
Nov 07, 2025 14:30 JST
Olympus Corporation (Olympus), a global MedTech leader dedicated to making people's lives healthier, safer, and more fulfilling, today unveiled a comprehensive strategy to transform endoscopy-enabled care through innovation and operational excellence.
More info..
HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus
Oct 31, 2025 08:30 JST
HighTide Therapeutics, Inc. (2511.HK), a biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic metabolic diseases, announced positive 52-week safety and efficacy results from the open-label extension (OLE) phases of two Phase III trials (SYMPHONY-1 and SYMPHONY-2) evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM).
More info..
HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus
Oct 31, 2025 08:30 JST
HighTide Therapeutics, Inc. (2511.HK), a biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic metabolic diseases, announced positive 52-week safety and efficacy results from the open-label extension (OLE) phases of two Phase III trials (SYMPHONY-1 and SYMPHONY-2) evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM).
More info..
HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus
Oct 31, 2025 08:30 JST
HighTide Therapeutics, Inc. (2511.HK), a biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic metabolic diseases, announced positive 52-week safety and efficacy results from the open-label extension (OLE) phases of two Phase III trials (SYMPHONY-1 and SYMPHONY-2) evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM).
More info..
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
Oct 30, 2025 13:43 JST
More info..
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
Oct 30, 2025 13:43 JST
More info..
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
Oct 30, 2025 13:43 JST
More info..
Olympus Introduces NBI+TXI(TM) Observation Mode to the EVIS X1(TM) Endoscopy System CV-1500 Video System Center
Oct 29, 2025 10:00 JST
Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer and more fulfilling, today announced the launch of the NBI+TXI(TM) observation mode, which combines Narrow Band Imaging (NBI(TM) mode) and Texture and Color Enhancement Imaging (TXI(TM) mode) into a single view.
More info..
Olympus Introduces NBI+TXI(TM) Observation Mode to the EVIS X1(TM) Endoscopy System CV-1500 Video System Center
Oct 29, 2025 10:00 JST
Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer and more fulfilling, today announced the launch of the NBI+TXI(TM) observation mode, which combines Narrow Band Imaging (NBI(TM) mode) and Texture and Color Enhancement Imaging (TXI(TM) mode) into a single view.
More info..
1
2
3
>>
Last
Releases By Industry
Business
Communications
CryptoCurrency
Financial
Industrial
Lifestyle
Medicine
Sustainablity
Technology